Expression of osteopontin and HGF/Met in adult soft tissue tumors

Cancer Biology and Therapy

Volumn 4, Issue 12, 2005, Pages 1336-1341

  Bramwell, Vivien H C ^a,b   Tuck, Alan B ^a   Wilson, Sylvia M ^a   Stitt, Larry W ^a   Cherian, Anil K ^a   Rorke, Stewart C ^a   Al Katib, Waleed ^a   Postenka, Carl O ^a   Chambers, Ann F ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Hepatocyte growth factor; Hepatocyte growth factor receptor; Met; Molecular markers; Osteopontin; Prognosis; Sarcoma

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; OSTEOPONTIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE TUMOR;

EID: 31144451464     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.12.2166     Document Type: Article

References (50)

1. Zahm SH, Fraumeni Jr JF. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504-14.
2. Brennan MF, Alektiar KM, Maki RG. Sarcomas of the soft tissue and bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:(Ch 39):1841-90.
3. O'Sullivan B, Bell RS, Bramwell VHC. Sarcomas of the soft tissues. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford Textbook of Oncology. 2nd ed. Oxford University Press, 2002:(Chapter 16.1):2495-2523.
4. AJCC Cancer Staging Handbook. 6th ed. 2002; 221-8.
5. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002; 20:627-9.
6. Borden EC, Baker LH, Bell RS, Bramwell V, Demetri G, Burton L, Eisenberg CDM, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram AT, van Oosterom JV, Waalen J, Weiss SW, Brennan MF. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res 2003; 9:1941-56.
7. O'Sullivan B, Pisters PW. Staging and prognostic factor evaluation in soft tissue sarcoma. Surg Oncol Clin N Am 2003; 12:333-53.
8. Furger KA, Menon RK, Tuck AB, Bramwell VHC, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1:621-32.
9. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90:1877-81.
10. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: Clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6:419-29.
11. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004; 121:228-41.
12. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from c-met protein. Nature 1989; 339:155-6.
13. Cortner J, Vande Woude GF, Rong S. The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. In: Goldberg ID, Rosen EM, eds. Epithelial-Mesenchymal Interactions in Cancer. Birkhauser Verlag Basel 1995; 89-121.
14. Cooper CS, Tempest PR, Beckman MP, Heldin CH, Brookes P. Amplification and over-expression of the met gene in spontaneously transformed NIH3T3 mouse fibroblasts. EMBO J 1986; 10:2623-8.
15. Rong S, Bodescot M, Blair D, Dunn J, Nakamura T, Mizuno K, Park M, Chan A, Aaronson S, Vande Woude GF. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12:5152-8.
16. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res 1993; 53:5355-60.
17. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-4.
18. Galimi F, Brizzi MF, Comoglio PM. The hepatocyte growth factor and its receptor. Stem Cells 1993; 2:22-30.
19. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narshimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78.
20. Motoi T, Ishida T, Kuroda M, Horiuchi H, Oka T, Matsumoto K, Nakamura T, Machinami R. Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma. Pathol Int 1998; 48:769-75.
21. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini PL, Cremona O, Campanacci M, Comoglio PM. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 1995; 10:739-49.
22. Scotlandi K, Baldini N, Olivero M, Di Renzo MF, Martano M, Serra M, Manara MC, Comoglio PM, Ferracini R. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 1996; 149:1209-19.
23. Coltella N, Manara MC, Cerisano V, Trusolino L, Di Renzo MF, Scotlandi K, Ferracini R. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003; 17:1162-4.
24. Ghoussoub RAD, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998; 82:1513-20.
25. Yamashita J-I, Ogawa M, Yamashita S-I, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54:1630-3.
26. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: Correlation with tumor progression. Int J Cancer 1997; 74:301-9.
27. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63:1101-5.
28. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10:202-11.
29. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998; 4:659-4.
30. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cellular Biochem 2000; 78:465-75.
31. Medico E, Gentile A, Lo Celso C, Williams A, Gambarotta G, Trusolino L, Comoglio PM. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res 2001; 61:5861-8.
32. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, Saad Z, Doig GS, Chambers AF. Osteopontin expression is a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79:502-8.
33. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996; 15:311-23.
34. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145:610-23.
35. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10:184-90.
36. Rudland PS, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley JHR, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62:3417-27.
37. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasiu W, Ishikawa T, Tahara E. Coexpression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998; 79:127-32.
38. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98:119-27.
39. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94:513-21.
40. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW. Predicting hepatitis B Virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9:416-23.
41. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002; 441:345-9.
42. Wallenius V, Hisaoka M, Helou K, Levan G, Mandahl N, Meis-Kindblom JM, Kindblom LG, Jansson JO. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol 2000; 156:821-9.
43. Ferracini R, Angelini P, Cagliero E, Linari A, Martano M, Wunder J, Buracco P. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 2000; 18:253-6.
44. Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 1997; 10:832-8.
45. Arihiro K, Inai K. Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma. Pathol Int 2001; 51:100-6.
46. Oda U, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: A clinicopathologic and immunohistochemical study. Hum Pathol 2000; 31:709-16.
47. Ferracini R, Olivero M, Di Renzo MF, Martano M, De Giovanni C, Nanni P, Basso G, Scotlandi K, Lollini P-L, Comoglio PM. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996; 12:1697-705.
48. Kuhnen C, Tolnay E, Steinau HU, Voss B, Muller KM. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch 1998; 432:337-42.
49. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 2000; 31:185-92.
50. Kuhnen C, Muehlberger T, Honsel M, Tolnay E, Steinau HU, Muller KM. Impact of c-Met expression on angiogenesis in soft tissue sarcomas: Correlation of micro vessel-density. J Cancer Res Clin Oncol 2003; 129:415-22.